|Over a week ago|
SWK Holdings initiated with a Buy at Dougherty » 08:0105/2705/27/20
Dougherty analyst Kyle…
Dougherty analyst Kyle Bauser initiated coverage of SWK Holdings with a Buy rating and $23 price target.
|Over a month ago|
SWK Holdings subsidiary appoints Rajiv Khosla as CEO » 08:0305/0405/04/20
SWK Holdings' wholly-owned subsidiary Enteris BioPharma, a biotechnology company developing drug products built around its proprietary delivery technologies, hired Rajiv Khosla, Ph.D., as CEO, effective immediately. Khosla replaces Joel Tune, Enteris' CEO since 2016. In 2011, Dr. Khosla founded CEUTEC LLC, a strategy and business development consultancy serving biopharmaceutical companies and venture capital firms. Khosla also worked with IntelGenx.
SWK Holdings authorizes share repurchase, provides COVID-19 update » 08:5603/2603/26/20
SWK Holdings provided an…
SWK Holdings provided an update regarding the evolving impact of the COVID-19 outbreak on the company's operations and the company's plans to repurchase its common stock. CEO Winston Black stated, "(...) Presently, we are pleased to report that, thus far, we believe our portfolio, like SWK, is holding firm against the challenges impacting the healthcare industry. We believe this is due to SWK's focus on investing in small and mid-sized life sciences companies with strong intellectual property protecting commercial products that fill a demand within the healthcare system, such as DxTerity Diagnostics, which today announced the development of a COVID-19 diagnostic test (...) Additionally, a number of our portfolio companies have publicly disclosed successful capital and equity raises over the past 12 months, as we disclosed in our portfolio update provided in February. (...) In response to the market dislocation of our stock price, the Board of Directors has authorized a stock repurchase program. We also anticipate that the unprecedented dislocation within the life sciences industry brought on by the coronavirus outbreak will create compelling investment opportunities given that many small to mid-sized healthcare companies with otherwise strong product offerings will be in the need of capital." SWK authorized the repurchase of up to an aggregate of $2.0M of the company's Common Stock from time to time. This program will expire on September 30 and replaces the program that expired on February 28. At this time, SWK has approximately $25M in cash and an additional $5M on our revolving credit facility should we need it to increase our cash position and preserve financial flexibility.
|Over a quarter ago|
SWK Holdings files to sell 9.19M shares of common stock for holders 16:5702/0702/07/20
SWK Holdings CEO tells The Fly optimistic about 2020 as trading starts on Nasdaq » 10:4502/0502/05/20
In an exclusive interview…
SWK Holdings commences trading on Nasdaq Capital Market » 08:0801/2301/23/20
SWK Holdings announced…
SWK Holdings announced that its shares of common stock will begin trading on the Nasdaq Capital Market beginning January 23 at 9:30 a.m., EST under the ticker symbol "SWKH."
SWK Holdings approved for listing on Nasdaq » 08:1401/2101/21/20
SWK Holdings announced…
SWK Holdings announced that its shares of common stock have been approved for listing on the Nasdaq Capital Market. Trading on the exchange is expected to commence on January 23 under the ticker symbol "SWKH."
SWK's Black sees company growing on all fronts » 15:2909/1109/11/19
SWK Holdings (SWKH) is a…
SWK Holdings (SWKH) is a specialized finance company with a specific focus on opportunities in the global healthcare sector. In an exclusive interview with The Fly, the company's CEO Winston Black discussed SWK's growth plans: "We're very much interested in evaluating situations where we can add to the technology that Enteris has and their capabilities. From a near-term acquisition perspective, it would be really transactions that look to bolster that platform. But overall, SWK is going to be growing on all fronts. In terms of Enteris and its recently announced Cara Therapeutics [CARA] license, we definitely expect that business to continue to grow. That was one of the reasons why we announced that we were going to be investing in their manufacturing capabilities. Currently, they're really only able to manufacture through Phase 2 and we think that's going to open up a lot of opportunities for them. On the specialty finance business, as we look at everything we've done over the last seven years and the platform that we've built, I think we've really become one of the go-to leverage providers in the space. And as we are becoming more entrenched in life sciences by acquiring Enteris, we will continue to see more and more interesting opportunities for us to execute upon. We expect both businesses to grow and bring opportunities one to the other." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.
SWK to continue to deploy capital in life science space, CEO says » 15:0409/1109/11/19
SWK Holdings (SWKH) is a…
SWK Holdings (SWKH) is a specialized finance company with a specific focus on opportunities in the global healthcare sector. In an exclusive interview with The Fly, the company's CEO Winston Black talked about ongoing opportunities: "The time of closing additional deals is always difficult to predict and it's somewhat uncertain, but there are a lot of very interesting opportunities that we're currently working on. That includes, of course, working with our existing portfolio companies and with their growth plans, as well as partnering with new folks as well. Based on everything that we're looking at, we do expect to continue to deploy capital in the life science space." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.
SWK CEO sees Enteris as platform for own royalties » 14:4409/1109/11/19
SWK Holdings (SWKH) is a…
SWK Holdings (SWKH) is a specialized finance company with a specific focus on opportunities in the global healthcare sector. In an exclusive interview with The Fly, the company's CEO Winston Black discussed Enteris BioPharma acquisition: "Royalties are a very meaningful part of our business. And one of the challenges with royalties is actually finding them and then being able to buy them - that's not necessarily the easiest thing to do. We really like the pharmaceutical royalty market and think there's a lot of potential there. Enteris potentially gives us our own platform to generate our own royalties and not having to go find them to purchase. From the finance business perspective, it's actually exciting. I think that by bringing the formulation in manufacturing, and operations into SWK, it improves SWK's standing within the life science ecosystem. I think we'll be able to have different conversations with folks as an operating entity than just a finance business. Because of that I think we can bring different relationships and perspectives to partners since we're going to be an operator ourselves. There is a lot of synergy between the finance business and Enteris' operations. We've also had some new opportunities arise from the Enteris side of SWK house. Regarding the integration, we're fully intending for the Enteris team to continue running the business. I wouldn't say we will be totally hands off on the business, as we're certainly going to be very involved and very interested in its ultimate success. But one of the appealing things about Enteris it that there is a very deep management team with a ton of technical and operational depth and knowledge that we don't have. We're going to need them to continue to run the business and our job is to help them run it better and invest in the business to grow in ways they weren't able to grow in the past." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.